Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/FX007> ?p ?o }
Showing triples 1 to 34 of
34
with 100 triples per page.
- FX007 abstract "FX007 is a selective small-molecule TrkA antagonist that is under development by Flexion Therapeutics for the local treatment of postoperative pain.[1] It is currently in the preclinical stage of development.[2] The drug was licensed by Flexion from AstraZeneca.[3] FX007 has also attracted interest as a potential treatment of osteoarthritis.".
- FX007 wikiPageExternalLink programs-pipeline.
- FX007 wikiPageExternalLink snapshot_article.asp?ticker=FLXN&page=2.
- FX007 wikiPageExternalLink flexion-therapeutics-reports-top-line-data-from-pivotal-phase-2b-clinical-trial-for-fx006-2015-09-08.
- FX007 wikiPageID "48183728".
- FX007 wikiPageLength "1391".
- FX007 wikiPageOutDegree "12".
- FX007 wikiPageRevisionID "685327120".
- FX007 wikiPageWikiLink AstraZeneca.
- FX007 wikiPageWikiLink Category:Analgesics.
- FX007 wikiPageWikiLink Category:Receptor_antagonists.
- FX007 wikiPageWikiLink Flexion_Therapeutics.
- FX007 wikiPageWikiLink Osteoarthritis.
- FX007 wikiPageWikiLink Pain.
- FX007 wikiPageWikiLink Pre-clinical_development.
- FX007 wikiPageWikiLink Receptor_antagonist.
- FX007 wikiPageWikiLink Small_molecule.
- FX007 wikiPageWikiLink Tanezumab.
- FX007 wikiPageWikiLink Tavilermide.
- FX007 wikiPageWikiLink Tropomyosin_receptor_kinase_A.
- FX007 wikiPageWikiLinkText "FX007".
- FX007 wikiPageUsesTemplate Template:Analgesic-stub.
- FX007 wikiPageUsesTemplate Template:Analgesics.
- FX007 wikiPageUsesTemplate Template:Nervous-system-drug-stub.
- FX007 wikiPageUsesTemplate Template:Neurotrophinergics.
- FX007 wikiPageUsesTemplate Template:Reflist.
- FX007 subject Category:Analgesics.
- FX007 subject Category:Receptor_antagonists.
- FX007 hypernym Antagonist.
- FX007 type Drug.
- FX007 comment "FX007 is a selective small-molecule TrkA antagonist that is under development by Flexion Therapeutics for the local treatment of postoperative pain.[1] It is currently in the preclinical stage of development.[2] The drug was licensed by Flexion from AstraZeneca.[3] FX007 has also attracted interest as a potential treatment of osteoarthritis.".
- FX007 label "FX007".
- FX007 wasDerivedFrom FX007?oldid=685327120.
- FX007 isPrimaryTopicOf FX007.